바운드리스 바이오BOLD 주가

Boundless Bio Q1 EPS $(0.60) Beats $(0.64) Estimate

Boundless Bio (NASDAQ:BOLD) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(0.64) by 4.76 percent. This is a 15.49 percent increase over losses of $(0.71) per share from the

Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights

Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940 $93 million in cash provides runway through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, May 08,...

[8-K] 중대 사건 — 8-K

[10-Q] 분기 실적 — 10-Q

[DEF 14A] 주주총회 위임장 — DEF 14A

[DEFA14A] DEFA14A — DEFA14A

[ARS] ARS — ARS

[8-K] 중대 사건 — 8-K

[10-K] 연 실적 — 10-K

[8-K] 중대 사건 — 8-K